EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?

Julia Schachenhofer, Victoria-Elisabeth Gruber, Stefanie Valerie Fehrer, Carmen Haider, Sarah Glatter, Ewa Liszewska, Romana Höftberger, Eleonora Aronica, Karl Rössler, Jacek Jaworski, Theresa Scholl iD, Martha Feucht

Neuropathology and Applied Neurobiology · 2024

DOI: 10.1111/nan.12974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2024. Verfasst von Julia Schachenhofer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Astrocytoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Tuberous Sclerosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tuberous sclerosis complex (TSC) is caused by variants in TSC1/TSC2 , leading to constitutive activation of the mammalian target of rapamycin (mTOR) complex 1. Therapy with everolimus has been approved for TSC, but variations in success are frequent. Recently, caudal late interneuron progenitor (CLIP) cells were identified as a common origin of the TSC brain pathologies such as subependymal giant cell astrocytomas (SEGA) and cortical tubers (CT). Further, targeting the epidermal growth factor receptor (EGFR) with afatinib, which is expressed in CLIP cells, reduces cell growth in cerebral TSC organoids. However, investigation of clinical patient‐derived data is lacking.

Aims

Observation of EGFR expression in SEGA, CT and focal cortical dysplasia (FCD) 2B human brain specimen and investigation of whether its inhibition could be a potential therapeutic intervention for these patients.

Methods

Brain specimens of 23 SEGAs, 6 CTs, 20 FCD2Bs and 17 controls were analysed via immunohistochemistry to characterise EGFR expression, cell proliferation (via Mib1) and mTOR signalling. In a cell‐based assay using primary patient‐derived cells (CT n = 1, FCD2B n = 1 and SEGA n = 4), the effects of afatinib and everolimus on cell proliferation and cell viability were observed.

Results

EGFR overexpression was observed in histological sections of SEGA, CT and FCD2B patients. Both everolimus and afatinib decreased the proliferation and viability in primary SEGA, tuber and FCD2B cells.

Conclusion

Our study demonstrates that EGFR suppression might be an effective alternative treatment option for SEGAs and tubers, as well as other mTOR‐associated malformations of cortical development, including FCD2B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberous SclerosisAstrocytomaHumansEverolimusAfatinibTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 1ErbB Receptors

Stichwörter der Autor:innen

EGFRSEGATSCafatinibfocal cortical dysplasiatubertuberous sclerosis complex

Substanzen

EverolimusAfatinibTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 1ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
  • International Institute of Molecular and Cell Biology, Warsaw, Poland.
  • Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.
  • Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, Netherlands.

ORCID-Profile: Theresa Scholl

Förderung

  • German Tuberous Sclerosis Foundation

Zitieren

APA

Schachenhofer, J., Gruber, V. E., Fehrer, S. V., Haider, C., Glatter, S., Liszewska, E., Höftberger, R., Aronica, E., Rössler, K., Jaworski, J., Scholl, T., & Feucht, M. (2024). Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.12974

Vancouver

Schachenhofer J, Gruber VE, Fehrer SV, Haider C, Glatter S, Liszewska E, et al. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?. Neuropathology and Applied Neurobiology. 2024. doi:10.1111/nan.12974

BibTeX
@article{Schachenhofer2024,
  author = {Schachenhofer, Julia and Gruber, Victoria-Elisabeth and Fehrer, Stefanie Valerie and Haider, Carmen and Glatter, Sarah and Liszewska, Ewa and Höftberger, Romana and Aronica, Eleonora and Rössler, Karl and Jaworski, Jacek and Scholl, Theresa and Feucht, Martha},
  title = {Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2024},
  doi = {10.1111/nan.12974}
}
Kostenlos starten →